- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05586880
Study to Evaluate Efficacy of EnXtra on Accuracy & Reaction Time, Perceived Alertness & Digital Fatigue for Video Gamers
A Randomized, Placebo-controlled, Double-blind Crossover Study to Evaluate Efficacy of EnXtra on Accuracy & Reaction Time, Perceived Alertness & Digital Fatigue for Video Gamers
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ms. Henali Bhoir, B Pharm
- Phone Number: 7738387606
- Email: henali.b@vediclifesciences.com
Study Locations
-
-
Maharashtra
-
Nerul, Maharashtra, India, 400 706
- Dr D Y Patil medical college
-
Thāne, Maharashtra, India, 400607
- Dr. Sarala Kataria Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males & Females aged ≥ 18 - ≤ 40 years.
- Subjects with Body Mass Index (BMI) 18 - 29.9 kg/ m2
- Subjects with history of playing video games for 6 or more hours/ week for 6 months before the screening
- Subject who can read and understand English language with ease.
- Fasting blood glucose (FBG) ≤ 125 mg/dl
- Subjects with history of regular sleep and agree to sleep for 8 ±1 hours the night before the visit day.
- Subjects who agree to maintain their usual dietary habits and level of exercise i.e. maintain their usual life-style throughout the trial period.
- Subjects willing to refrain from consuming alcohol 24 hours prior to the visit days.
- Subjects willing to refrain from consuming caffeine and caffeine-containing products 24 hour prior to visit days.
- Willing to participate in the study with a signed and dated written consent.
Exclusion Criteria:
- Subjects suffering from Insomnia.
- Subjects suffering from chronic fatigue, stress or anxiety.
- Subjects with uncontrolled hypertension with systolic blood pressure ≥130 and diastolic blood pressure ≥89 mm Hg.
- Subjects with uncontrolled Type II Diabetes Mellitus with FBG >125 mg/ dl
- Subjects with Hemoglobin (Hb) ≤ and/or ≥ 13.5 - 17.0 g/Dl inmales and 12.0 - 15.0 g/dL in females.
- Subjects with ≤ and/or ≥ Total Leucocyte Counts (TLC) 4.0 - 10.0 x 10 3/U
- Subjects with Differential Leukocyte Counts (DLC) outside the normal range. [Neutrophils: 40 - 80 %, Lymphocytes: 20 - 40 %, Monocytes: 2 - 10 %, Eosinophils: 1 - 6 %, Basophils: 0 - 0.02 %]
- Subjects with AST values ≤ and/or ≥ 40 U/L in males and 32 U/Lin females.
- Subjects with ALT values ≤ and/or ≥ 41 U/L in males and 33 U/Lin females
- Subjects with Creatinine ≤ and/or ≥ Males: 59-104 μmol/L in males and 45-84 μmol/L in females
- History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders.
- Chronic Alcoholics and smokers
- Subjects taking any medications or preparations to improve gaming performance (herbal, dietary supplements, homeopathic preparations, etc.) and/or cognitive performance during the study.
- Subjects who have any other disease or condition, or are using any medication, that in the judgment of the investigator may interfere with evaluations in the study or noncompliance with treatment or visits.
- Subjects who are on anxiolytics, anti-depressants, antipsychotics, anticonvulsants, antihypertensive, centrally acting corticosteroids, opioid pain relievers, hypnotics, and/or prescribed sleep medications.
- Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
- Subjects who have had participated in a study of an investigational product 90 days prior to the screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EnXtra 300 mg/ capsule
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
|
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
|
Placebo Comparator: Microcrystalline cellulose (MCC) 300mg
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
|
One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reaction Accuracy
Time Frame: Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & 3 hours post IP on Day 5; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & 3 hours post IP on Day 15
|
Reaction Accuracy as assessed by change in the accuracy score for the video game (Call of Duty) as compared to the placebo
|
Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & 3 hours post IP on Day 5; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & 3 hours post IP on Day 15
|
Reaction Time
Time Frame: Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & 3 hours post IP on Day 5; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & 3 hours post IP on Day 15
|
Reaction Time as assessed by change in the time to response using stroop effect as compared to the placebo
|
Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & 3 hours post IP on Day 5; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & 3 hours post IP on Day 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TIME
Time Frame: Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & 3 hours post IP on Day 5; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & 3 hours post IP on Day 15
|
Time taken to complete the mission for the video game (Call of Duty) as compared to the placebo
|
Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & 3 hours post IP on Day 5; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & 3 hours post IP on Day 15
|
Stanford Sleepiness Scale
Time Frame: Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Perceived Alertness after video game assessed by change in Stanford Sleepiness Scale (SSS) after video game session, as compared to that of placebo Higher the score is the worst outcome and lowest the score is the better outcome. |
Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Multidimensional Fatigue Inventory mental domain scores
Time Frame: Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Mental fatigue as assessed by change in Multidimensional Fatigue Inventory (MFI) mental domain scores at the end of the video game, as compared to the placebo The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue.
It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity.
This tool has been tested for its psychometric properties in individuals receiving radiotherapy, those with the chronic fatigue syndrome, psychology students, medical students, army recruits and junior physicians
|
Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP & Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Multidimensional Fatigue Inventory physical domain scores
Time Frame: Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP, Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Physical fatigue as assessed by change in Multidimensional Fatigue Inventory (MFI) physical domain score at the end of the video game, as compared to the placebo The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue.
It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity.
This tool has been tested for its psychometric properties in individuals receiving radiotherapy, those with the chronic fatigue syndrome, psychology students, medical students, army recruits and junior physicians
|
Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP, Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Multidimensional Fatigue Inventory (MFI) motivation domain scores
Time Frame: Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP, Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Intrinsic motivation for video gaming as assessed by change in the Multidimensional Fatigue Inventory (MFI) motivation domain scores after game session, as compared to placebo. The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue. It covers the following dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. This tool has been tested for its psychometric properties in individuals receiving radiotherapy, those with the chronic fatigue syndrome, psychology students, medical students, army recruits and junior physicians |
Day 1 - Pre - IP (Baseline), Day 1 - 3 hours post IP, Day 5 - 3 hours post IP; Day 10 - Pre - IP (Baseline), Day 10 - 3 hours post IP & Day 15 - 3 hours post IP
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OM/220502/ENXTRA/RTPADF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alert Fatigue, Health Personnel
-
Gurkan KAPIKIRANRecruitingOccupational Stress | Alert Fatigue, Health PersonnelTurkey
-
University Hospital Bispebjerg and FrederiksbergOdense University Hospital; Rigshospitalet, Denmark; Hvidovre University Hospital and other collaboratorsRecruitingDeterioration, Clinical | Alert Fatigue, Health PersonnelDenmark
-
Massachusetts General HospitalCompletedSepsis | Infections, Bacterial | Alert Fatigue, Health PersonnelUnited States
-
Indiana UniversityIndiana University Health; Daniel F. Evans Center for Spiritual and Religious...CompletedHealth Personnel AttitudeUnited States
-
The Reading Hospital and Medical CenterCompletedAttitude of Health PersonnelUnited States
-
Tata Memorial CentreCompletedHealth Knowledge, Attitudes, Practice | Health Personnel AttitudeIndia
-
Boston Children's HospitalAssociation of Pediatric Program DirectorsCompleted
-
University of New MexicoCompleted
-
National Taiwan University HospitalUnknownAttitude of Health Personnel
-
Clinica Universidad de Navarra, Universidad de...Government of NavarraCompletedSmoking Cessation | Health Behavior | Health Personnel AttitudeSpain
Clinical Trials on Experimental: EnXtra 300 mg/ capsule
-
Vedic Lifesciences Pvt. Ltd.Not yet recruitingUpper Respiratory Tract InfectionsIndia
-
SandozCompleted
-
SandozCompleted
-
VM Oncology, LLCRecruitingSarcoma | Cervical Cancer | Breast Cancer | Adenoid Cystic Carcinoma | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Thymic Carcinoma | Lung Cancer | Mesothelioma | Bladder Cancer | Head and Neck Carcinoma | Any Solid Tumors Progressed After a Prior ImmunotherapyUnited States, Puerto Rico
-
GlaxoSmithKlineCompleted
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, PulmonaryUnited States
-
Mochida Pharmaceutical Company, Ltd.CompletedSteatohepatitisUnited States, Puerto Rico
-
Joseph JurcicBristol-Myers SquibbTerminatedMyeloproliferative NeoplasmUnited States
-
Tasly Pharmaceutical Group Co., LtdRecruiting